Fr480 PHARMACOLOGICAL CHARACTERIZATION OF AJM347: A NOVEL, ORALLY ACTIVE AND SMALL MOLECULAR PRODRUG OF ALPHA 4 BETA 7-SPECIFIC INTEGRIN ANTAGONIST FOR INFLAMMATORY BOWEL DISEASE

Andou, Ayatoshi; Yamaura, Yui; Sugiyama, Tomoko; Saitou, Yuki; Uo, Michihide

doi:10.1016/s0016-5085(21)01501-8

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both AJM347 and its active metabolite CAN2281 are gut selective. 41 The Phase I trial showed the molecule to be well absorbed orally and safe. It maintained selective inhibition of MAdCAM-1 binding to α4β7 integrin on peripheral blood CD4+ T cells without altering the lymphocyte counts in the cerebrospinal fluid (CSF).…”

Section: Anti-lymphocyte Traffickingmentioning

confidence: 99%

See 1 more Smart Citation

Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials

AlAmeel,

AlMutairdi,

Al-Bawardy

2023

CEG

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic and progressive inflammatory disorder that affects the colon. The advent of advanced therapies such as biologic agents and small molecules has revolutionized the management of UC. Despite the expanding therapeutic armamentarium of advanced therapies to treat UC, the overall net remission rates and durability of currently available agents are relatively low. This highlights the need for further drug development and more innovative clinical trial design. There are currently multiple emerging agents in the pipeline for the management of UC. This includes agents with alternative routes of administration such as oral or subcutaneous tumor necrosis factor inhibitors or novel mechanisms of action such as toll-like receptor 9 (TLR9) agonist cobitolimod and phosphodiesterase 4 inhibitor apremilast. In this review, we will highlight novel and emerging advanced therapies currently in the pipeline for the management of UC.

show abstract

Section: Anti-lymphocyte Traffickingmentioning

confidence: 99%

“…It maintained selective inhibition of MAdCAM-1 binding to α4β7 integrin on peripheral blood CD4+ T cells without altering the lymphocyte counts in the cerebrospinal fluid (CSF). 41 No phase II/III studies are currently registered for AJM347 in UC.…”

Section: Anti-lymphocyte Traffickingmentioning

confidence: 99%